TXG
NASDAQ10x Genomics Inc.
News · 26 weeks48+43%
2025-12-142026-06-07
Mix2590d
- Insider11(44%)
- Other7(28%)
- SEC Filings4(16%)
- Earnings2(8%)
- Analyst1(4%)
Latest news
25 items- INSIDERDirector Teichmann Sarah A. was granted 8,829 shares, increasing direct ownership by 33% to 35,609 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Suliman Shehnaaz was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Stuelpnagel John R was granted 8,829 shares, increasing direct ownership by 2% to 368,436 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Popovits Kimberly J was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Mateo Alan was granted 8,829 shares, increasing direct ownership by 11% to 85,877 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Kosaraju Sridhar was granted 8,829 shares, increasing direct ownership by 16% to 65,278 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SEC10x Genomics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - 10x Genomics, Inc. (0001770787) (Filer)
- INSIDERChief Executive Officer Saxonov Serge sold $709,057 worth of shares (28,893 units at $24.54) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,138,380 units (SEC Form 4) to satisfy withholding tax4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDEROfficer Hindson Benjamin J. sold $283,399 worth of shares (11,595 units at $24.44), decreasing direct ownership by 2% to 502,000 units (SEC Form 4) to satisfy tax liability4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERChief Financial Officer Taich Adam sold $369,018 worth of shares (15,098 units at $24.44), decreasing direct ownership by 4% to 379,898 units (SEC Form 4) to cover taxes4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PR10x Genomics Reports First Quarter 2026 Financial ResultsPLEASANTON, Calif., May 7, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2026. Recent Updates Revenue was $150.8 million for the first quarter of 2026, representing a 3% decrease over the corresponding period of 2025. Excluding $16.8 million related to one-time license and royalty revenue in the first quarter of 2025, revenue increased 9% over the corresponding period of 2025.Launched Atera, a new platform to redefine how biology is measured and understood.
- SEC10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 10x Genomics, Inc. (0001770787) (Filer)
- PR10x Genomics to Participate in the BofA Securities 2026 Healthcare ConferencePLEASANTON, Calif., April 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2026 Healthcare Conference on Wednesday, May 13, at 5:00 p.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10
- PRThe Quiet Rule Change Tilting $10B Toward Medtech's Most Validated PlatformsIssued on behalf of VentriPoint Diagnostics Ltd.VANCOUVER, BC, April 29, 2026 /CNW/ -- Equity-Insider.com News Commentary – Here's the quiet shift in medtech right now: the global medical imaging market is on track to grow from $41.64 billion in 2024 to $67.87 billion by 2034[1], and capital has stopped chasing every shiny promise. That pressure got real in April, when the FDA advanced its real-world evidence framework for medical devices[2], lining regulators and payers up around documented performance instead of trial-stage pitches. Five names keep showing up in that conversation: VentriPoint Diagnostics (TSXV:VPT) (OTCPK: VPTDF), Senseonics (NASDAQ:SENS), TransMedics Group (NASDAQ:TMDX),
- SECSEC Form DEFA14A filed by 10x Genomics Inc.DEFA14A - 10x Genomics, Inc. (0001770787) (Filer)
- SECSEC Form DEF 14A filed by 10x Genomics Inc.DEF 14A - 10x Genomics, Inc. (0001770787) (Filer)
- PR10x Genomics Introduces Atera, a New Platform to Redefine How Biology is Measured and UnderstoodEnables Whole-Transcriptome In Situ Spatial Biology with Single-Cell Sensitivity at ScaleDebuts at AACR Annual Meeting 2026 with Data from Leading Research Institutions, Including the June Lab at the Perelman School of Medicine, University of Pennsylvania and German Cancer Research Institute (DKFZ)PLEASANTON, Calif., April 18, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today announced Atera, a new in situ spatial biology platform engineered to deliver whole-transcriptome spatial analysis with single-cell sensitivity at unprecedented scale.
- INSIDERSEC Form 4 filed by Saxonov Serge4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PR10x Genomics to Report First Quarter 2026 Financial Results on May 7, 2026PLEASANTON, Calif., April 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2026 after market close on Thursday, May 7, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's
- ANALYST10x Genomics upgraded by William BlairWilliam Blair upgraded 10x Genomics from Mkt Perform to Outperform
- INSIDERSEC Form 4 filed by Saxonov Serge4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- PRBioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical LabsThe global initiative aims to profile up to 100,000 patient specimens to scale M-Optimus, the world model of biology, representing a ~20x increase in scale over existing data available in the world todayThe Launch of STELA: Bioptimus is establishing the largest clinically linked multimodal atlas, starting in oncology and immunology tissue, designed to generate harmonized multi-omics patient data.A Strategic Partnership with 10x Genomics: Leveraging the Xenium spatial transcriptomics platform as the foundational partner for the launch, the initiative sets a new benchmark for reproducible, AI-ready data generation across leading research institutions worldwide.A Strategic Partnership with the
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- PRPerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient - - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine -SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the publ
TXG FAQ
7 questionsWhat does 10x Genomics Inc. do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their...Where does TXG stock trade?
10x Genomics Inc. (TXG) is listed on NASDAQ.What sector and industry is TXG in?
10x Genomics Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did 10x Genomics Inc. go public?
10x Genomics Inc. (TXG) completed its IPO in 2019.What are analysts saying about TXG?
10x Genomics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-03-31. Recent price targets range from $1200.00 to $3500.00.What companies are similar to TXG?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare TXG side-by-side with any of them on Quantisnow.How can I track TXG on Quantisnow?
Quantisnow aggregates 10x Genomics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TXG to receive live email and push alerts on every new disclosure.